Responses

Original research
Trends in acid suppressant drug prescriptions in primary care in the UK: a population-based cross-sectional study
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Re: Re: Trends in acid suppressant drug prescriptions in primary care in the UK
    • Devin Abrahami, Graduate student McGill University
    • Other Contributors:
      • Laurent Azoulay, Assoicate professor

    We thank the author for their interest in our paper on the prescribing trends of acid suppressant drugs in the UK.1 Our paper found that new users of proton pump inhibitors (PPIs) were slightly older than new users of histamine-2 receptor antagonists (H2RAs), though the prevalence of both drug classes increases with age. As highlighted by the meta-analysis by Wang et al. the observational evidence regarding the risk of dementia associated with acid suppressant use has been inconclusive, with some studies finding an increased risk and others a decreased risk.2 Based on the pooled estimates of 17 studies, the authors did not conclude that the use of acid suppressant drugs is associated with an increased risk of dementia. An important aspect of these studies is that acid suppressant users were compared to non-users, which makes it challenging to separate the effects of the drug from the underlying indication, limiting conclusions that may be drawn regarding the dementia risk. However, as described in our paper,1 there are other serious adverse effects associated with the use of PPIs that have not been associated with H2RAs, including gastrointestinal malignancies, H. pylori infection and hypomagnesemia. We agree with the author that certain indications favour the prescribing of PPIs over H2RAs, though a careful assessment of the risk-benefit profile is warranted.

    References
    1. Abrahami D, McDonald EG, Schnitzer M, et al. Trends in acid suppressant drug prescripti...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Re: Trends in acid suppressant drug prescriptions in primary care in the UK

    Abrahami et al. examined proton pump inhibitor (PPI) and histamine-2 receptor antagonist (H2RA) prescribing patterns over a long period in primary care in the UK (1). From 1990 to 2018, PPI prevalence increased from 0.2% to 14.2%, while H2RA prevalence were under 3.4%. The authors described that PPIs were associated with a number of adverse effects not attributed to H2RAs, and recommended H2RAs as a valuable treatment as acid suppressants. I have a comment about the study with special reference to dementia risk.

    Prescribing acid suppressants is more prevalent in the elderly. Wang et al. conducted a meta-analysis to investigate the risk of acid suppressants on dementia (2). The pooled adjusted hazard ratios (95% confidence intervals) of PPI users and H2RA users for the development of dementia were 0.98 (0.85-1.13) and 1.20 (0.98-1.47), respectively. Although there is no significant association regarding the effect of acid suppressants on the development of dementia, H2RA presented a trend of increased risk for dementia. There are medical reasons of prescribing PPIs instead of H2RAs, and evidence should be presented for concluding the higher adverse effects of PPIs than H2RAs.

    References
    1. Abrahami D, McDonald EG, Schnitzer M, et al. Trends in acid suppressant drug prescriptions in primary care in the UK: a population-based cross-sectional study. BMJ Open 2020;10(12):e041529.
    2. Wang H, Tian L, Yan X. No association between acid suppressant use and...

    Show More
    Conflict of Interest:
    None declared.